Home » Posts tagged 'alan green'
Tag Archives: alan green
Mirriad #MIRI CEO Stephan Beringer discusses the group’s AI powered advertising technology and recent trading with Alan Green
Mirriad #MIRI CEO Stephan Beringer discusses the group’s AI powered advertising technology and recent trading with Novus Communications CEO Alan Green. Mirriad’s innovative advertising solution reaches consumers watching content, offering something new to the film and TV industry. Newly appointed CEO, Stephan Beringer, talks to Alan Green about their position within the advertising space, and how machine learning technology can be utilised to improve advertising for both the company and the consumer.
It’s been an exceptionally busy few months for Open Orphan (ORPH) and its Executive Chairman Cathal Friel.
Since reversing into Venn Life Sciences last summer, Open Orphan has set it’s sights on a series of acquisitions to forge a specialist pharmaceutical services group with a focus on orphan drugs. In raising the money to complete the Venn Life Sciences and recent hVIVO acquisitions, Friel has invested over £2m of his own money through his investment vehicle Raglan Capital into Open Orphan. His investments are locked in until three years after the IPO in June 2019.
In 2018, over 50% of new FDA approved drugs were classed as ‘orphan’, i.e. treat rare diseases.
With this in mind, Friel and his team have constructed a vehicle to acquire and consolidate a number of smaller companies into a larger profitable pharma services company. Within this there is Open Orphan Genomic Health Data, using AI tools to build a valuable database of patient information using a low cost data collection methodology.
In the run up to the end of 2019, ORPH struck several three year contract agreements and collaborations lucrative partnership agreements and collaborations, most notably with French pharma giant Ipsen Group, Japanese pharma company Carna and a Tier 1 German pharma company as part of moving the original Venn business away from short term ad-hoc contracts towards longer more sustainable contracts.
The acquisition promised at Open Orphan’s launch last summer came to fruition in December, when the company announced the acquisition of hVIVO, a world leader in the provision of viral challenge study services to companies developing vaccines for viruses.
The deal offered 2.47 shares for each hVIVO share, providing its shareholders with a 33% uplift. Open Orphan also broke the mould by moving fast in a slow moving sector as this takeover was recorded as one of the fastest in 7 years for the London market, completing as it did in just 38 days. More importantly, the economies of scale the merger delivers greatly broadens Open Orphan’s in-house clinical offering and opportunities to commercialise the existing deal pipeline.
Both Venn and more importantly hVIVO had been chronically loss making, however given the compelling synergies, the Open Orphan team led by Friel are optimistic that the enlarged Group will be profitable by June 2020 if not before.
To maximise on the opportunities generated by the acquisition, a further £5.3m fundraise was completed at the end of January 2020, conducted at a small premium to market price and with a minimum fundraise of £2.5m once again underwritten by Friel’s investment vehicle. The raise was oversubscribed, predominantly funded by institutional investors and at a good premium to the IPO fundraise in June 2019. Added to this, Friel personally invested £300k.
As part of the hVIVO acquisition, Open Orphan now owns the largest quarantine facility in N Europe, with 24 quarantine bedrooms at Queen Mary’s Hospital in London.
As things currently stand, this facility may potentially be used for ill patients patients during the current Coronavirus crisis that is gripping China and slowly spreading to other countries.
Professor John Oxford, one of the original founders of hVIVO is also a world-leading expert on Coronavirus and virology. In this capacity he has appeared across numerous TV and radio programmes over the past week, and is also an advisor and consultant to Cathal Friel and the enlarged Open Orphan Group.
The coming days will see more information emerge about Open Orphan and hVivo’s capabilities surrounding virology, vaccines and the quarantine facility.
To keep up to speed with this fast moving company, the latest copy of the Open orphan investor presentation is now available to view on https://www.openorphan.com/investors/reasons-invest.
Alan Green – February 2020
Alan Green discusses Mirriad #MIRI, i3 Energy #I3E, Polarean Imaging #POLX and Fair Oaks Income #FAIR on Vox Markets podcast
Alan Green and Justin Waite discusses Mirriad #MIRI, i3 Energy #I3E, Polarean Imaging #POLX & Fair Oaks Income #FAIR on the Vox Markets podcast. We also talk about: Open Orphan #ORPH & Vanguard’s FTSE U.K. Equity Income Index Fund – Accumulation.
Alan Green discusses Open Orphan #ORPH, Mirriad Advertising #MIRI and IXICO #IXI on Vox Markets podcast
Alan Green discusses Open Orphan #ORPH, Mirriad Advertising #MIRI and IXICO #IXI with Justin Waite on the Vox Markets podcast.
Alan Green talks Cadence Minerals #KDNC, Open Orphan #ORPH, Bidstack #BIDS and Kibo Energy #KIBO on the Vox Markets podcast
I discuss the investment proposition for Cadence Minerals #KDNC, Open Orphan #ORPH following the hVIVO #HVO all share merger, Bidstack #BIDS and Kibo Energy #KIBO. The interview is 21 minutes in.
Open Orphan #ORPH CEO Cathal Friel & Cadence Minerals #KDNC CEO Kiran Morzaria discuss developments on Vox Markets podcast
Open Orphan #ORPH CEO Cathal Friel discusses the all share offer for hVIVO #HVO & Cadence Minerals #KDNC CEO Kiran Morzaria discusses the reinstatement of critical railway concessions at the Amapa Iron ore project with Justin Waite on the Vox Markets podcast. ORPH podcast at start. Cadence podcast at 21 minutes.